Cancer Clinical Trial
Official title:
Tumor Associated Antigen-specific Engineered Immune Effector Cells (EIE) Against Cancer
The primary objectives are to evaluate the safety and efficacy of infusion of autologous tumor associated antigen-specific engineered immune effector cells (EIE).
Malignant tumor is still a major challenge in medicine and requires technology breakthrough,
and its mortality rate is the highest among all diseases. World Health Organization and the
American Cancer Association expect about 12 million new cancer patients worldwide each year,
with about 8 million cancer deaths (20 thousand cancer deaths per day). At present, more than
20 million people are suffering from cancer, and this figure will increase to 75 million in
2030. In Asia, the incidence of cancer is expected to rise by 60% in 2020, and the number of
cancer related deaths will reach 7 million annually in 2030. The incidence of lung,
Intestine, breast, prostate and gastric cancer is high, and lung, Intestine, breast and liver
cancer are the main causes of cancer related deaths in Asia.
Adoptive immunotherapy based on cytotoxic T lymphocytes reactive with specific antigens has
proven to be effective. In vitro induction of tumor antigen-specific immune cells and
engineering of target specific immune cells have great potential for cancer eradication. The
study aims to evaluate the safety and efficacy of ex vivo manipulated EIE cells including
chimeric antigen receptor (CAR) modified immune cells in treating cancer. The primary study
objectives are to evaluate the safety of the investigational product, autologous EIE cells,
to subjects by intravenous and intratumoral injection. The secondary study objectives are (1)
to evaluate the success rate of generating autologous EIE cells ex vivo, and (2) to determine
the anti-cancer efficacy of the EIE cells.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|